Nature Communications (Sep 2021)
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
- Amand F. Schmidt,
- Nicholas B. Hunt,
- Maria Gordillo-Marañón,
- Pimphen Charoen,
- Fotios Drenos,
- Mika Kivimaki,
- Deborah A. Lawlor,
- Claudia Giambartolomei,
- Olia Papacosta,
- Nishi Chaturvedi,
- Joshua C. Bis,
- Christopher J. O’Donnell,
- Goya Wannamethee,
- Andrew Wong,
- Jackie F. Price,
- Alun D. Hughes,
- Tom R. Gaunt,
- Nora Franceschini,
- Dennis O. Mook-Kanamori,
- Magdalena Zwierzyna,
- Reecha Sofat,
- Aroon D. Hingorani,
- Chris Finan
Affiliations
- Amand F. Schmidt
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Nicholas B. Hunt
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
- Maria Gordillo-Marañón
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Pimphen Charoen
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Fotios Drenos
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Mika Kivimaki
- Department of Epidemiology and Public Health, University College London
- Deborah A. Lawlor
- MRC Integrative Epidemiology Unit at the University of Bristol
- Claudia Giambartolomei
- Istituto Italiano di Tecnologia, Central RNA Lab
- Olia Papacosta
- Primary Care and Population Health, University College London
- Nishi Chaturvedi
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Joshua C. Bis
- Cardiovascular Health Research Unit, Department of Medicine, University of Washington
- Christopher J. O’Donnell
- Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School
- Goya Wannamethee
- Primary Care and Population Health, University College London
- Andrew Wong
- MRC Unit for Lifelong Health and Ageing at UCL
- Jackie F. Price
- Usher Institute, University of Edinburgh
- Alun D. Hughes
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Tom R. Gaunt
- MRC Integrative Epidemiology Unit at the University of Bristol
- Nora Franceschini
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina
- Dennis O. Mook-Kanamori
- Department of Clinical Epidemiology, Leiden University Medical Center
- Magdalena Zwierzyna
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Reecha Sofat
- Institute of Health Informatics, University College London
- Aroon D. Hingorani
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- Chris Finan
- Institute of Cardiovascular Science, Faculty of Population Health, University College London
- DOI
- https://doi.org/10.1038/s41467-021-25703-3
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 10
Abstract
Despite being studied in clinical trials, CETP inhibitors are not yet an approved treatment for coronary heart disease. Here, by analyzing results from clinical trials and drug target mendelian randomization studies, the authors demonstrate that previous failure of CETP inhibitors are likely compound and not drug target-related.
